Prothrombin complex concentrates: Difference between revisions
Ostermayer (talk | contribs) (→Common) |
ClaireLewis (talk | contribs) |
||
(4 intermediate revisions by 4 users not shown) | |||
Line 3: | Line 3: | ||
*Dosage Forms:lypophilized concentrate for reconstitution 500u/vial and 1000u/vial | *Dosage Forms:lypophilized concentrate for reconstitution 500u/vial and 1000u/vial | ||
*Common Trade Names: Kcentra | *Common Trade Names: Kcentra | ||
*3 factor PCC (Factors II, IX, and X), would need to supplement with factor VII for reversal if using 3 factor PCC | |||
*4 factor PCC (Factors II, VII, IX, and X) | |||
==Adult Dosing== | ==Adult Dosing== | ||
Line 9: | Line 11: | ||
**INR 4-6: 35units/kg, not to exceed 3500 units | **INR 4-6: 35units/kg, not to exceed 3500 units | ||
**INR >6: 50units/kg, not to exceed 5000 units | **INR >6: 50units/kg, not to exceed 5000 units | ||
* | *Consider rechecking INR after 15 minutes to determine need for redosing | ||
==Pediatric Dosing== | ==Pediatric Dosing== | ||
Safety and efficacy not established | *Safety and efficacy not established | ||
==Special Populations== | ==Special Populations== | ||
Line 33: | Line 35: | ||
===Common=== | ===Common=== | ||
*Thromboembolic events | *Thromboembolic events | ||
*[[ | *[[Headache]] | ||
*[[ | *[[Hypotension]] (4.9%) | ||
*[[ | *[[Nausea/vomiting]] | ||
* | *Arthralgia | ||
*[[ICH]] (2.9%) | *[[ICH]] (2.9%) | ||
* | *Mental status change | ||
* | *Hypertension (2.9%) | ||
==Pharmacology== | ==Pharmacology== | ||
Line 49: | Line 51: | ||
==See Also== | ==See Also== | ||
*[[Blood | *[[Anticoagulant reversal for life-threatening bleeds]] | ||
*[[ | *[[Anti-platelet agent reversal]] | ||
*[[Blood products]] | |||
*[[Warfarin reversal]] | |||
==References== | ==References== | ||
<references/> | <references/> | ||
[[Category:Pharmacology]] | [[Category:Pharmacology]] | ||
[[Category:Heme/Onc]] |
Revision as of 22:09, 23 September 2019
General
- Type: Hemostatics, blood components
- Dosage Forms:lypophilized concentrate for reconstitution 500u/vial and 1000u/vial
- Common Trade Names: Kcentra
- 3 factor PCC (Factors II, IX, and X), would need to supplement with factor VII for reversal if using 3 factor PCC
- 4 factor PCC (Factors II, VII, IX, and X)
Adult Dosing
- Based on pretreatment INR, units based on factor 9 content
- INR 2-4: 25units/kg, not to exceed 2500 units
- INR 4-6: 35units/kg, not to exceed 3500 units
- INR >6: 50units/kg, not to exceed 5000 units
- Consider rechecking INR after 15 minutes to determine need for redosing
Pediatric Dosing
- Safety and efficacy not established
Special Populations
- Pregnancy Rating: C
- Lactation: Unknown, breast feeding not advised
- Renal Dosing
- Adult-N/A
- Pediatric-N/A
- Hepatic Dosing
- Adult-N/A
- Pediatric-N/A
Contraindications
Serious
- Patients receiving PCC for reversal of a vitamin K antagonist (Warfarin) due to life-threatening bleeding have a rate of thromboembolism which is similar to the rate in patients who receive Fresh frozen plasma (7.3% v 7.1%).[1]
Common
- Thromboembolic events
- Headache
- Hypotension (4.9%)
- Nausea/vomiting
- Arthralgia
- ICH (2.9%)
- Mental status change
- Hypertension (2.9%)
Pharmacology
- Half-life: 4-60 hours, depending on clotting factor
- Metabolism:
- Excretion:
- Mechanism of Action: 4 factor PCC contains factors II, VII, XI, X, protein C and S
See Also
- Anticoagulant reversal for life-threatening bleeds
- Anti-platelet agent reversal
- Blood products
- Warfarin reversal
References
- ↑ Milling, TJ Jr et al. Thromboembolic events after vitamin K antagonist reversal with 4-factor prothrombin complex concentrate: exploratory analyses of two randomized, plasma-controlled studies. Ann Emerg Med. 2016 Jan;67(1):96-105. PMID: 26094105